Cargando…

Immune Response to CoronaVac and Its Safety in Patients with Type 2 Diabetes Compared with Healthcare Workers

Background: Vaccines for SARS-CoV-2 have been critical for preventing disease. Previous research showed patients with diabetes have impaired immunity. This study aimed to determine the immunity to coronavirus after CoronaVac by comparing patients with type 2 diabetes (T2D) and healthcare workers (HC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dechates, Bothamai, Porntharukchareon, Thachanun, Sirisreetreerux, Supamas, Therawit, Phonthip, Worawitchawong, Supanat, Sornsamdang, Gaidganok, Soonklang, Kamonwan, Tawinprai, Kriangkrai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10052125/ https://www.ncbi.nlm.nih.gov/pubmed/36992267 http://dx.doi.org/10.3390/vaccines11030684

Ejemplares similares

Dynamics of anti-RBD (anti-receptor binding domain) levels in diabetes patients following the ChAdOx1 nCoV-19 vaccine (AZD1222) in the Thai population
por: Sirisreetreerux, Supamas, et al.
Publicado: (2023)

Antibody levels in people with diabetes after one dose of the ChAdOx1 nCoV-19 (AZD1222) vaccine
por: Rangsrisaeneepitak, Vimonsri, et al.
Publicado: (2022)

Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population
por: Tawinprai, Kriangkrai, et al.
Publicado: (2022)

Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines
por: Cohen, Guy, et al.
Publicado: (2022)

Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial
por: Tawinprai, Kriangkrai, et al.
Publicado: (2022)

The immunogenicity of the ChAdOx1 nCoV-19 vaccination in participants with underlying comorbidity diseases: A prospective cohort study
por: Porntharukchareon, Thachanun, et al.
Publicado: (2023)

Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study
por: Tawinprai, Kriangkrai, et al.
Publicado: (2023)

Safety and Immunogenicity of the BBIBP-CorV Vaccine in Adolescents Aged 12 to 17 Years in the Thai Population: An Immunobridging Study
por: Tawinprai, Kriangkrai, et al.
Publicado: (2022)

Effectiveness of CoronaVac in preventing COVID-19 in healthcare workers
por: Bayhan, Gulsum Iclal, et al.
Publicado: (2022)

Anaphylaxis is rare due to CoronaVac in a population of healthcare workers
por: Öztürk, Betül Özdel, et al.
Publicado: (2022)

Boosting immunity after CoronaVac
por: Sester, Martina, et al.
Publicado: (2022)

Effect of Inactivated SARS-CoV-2 Vaccines and ChAdOx1 nCoV-19 Vaccination to Prevent COVID-19 in Thai Households (VacPrevent trial)
por: Muadchimkaew, Marisa, et al.
Publicado: (2022)

Immunogenicity of Mix-and-Match CoronaVac/BNT162b2 Regimen versus Homologous CoronaVac/CoronaVac Vaccination: A Single-Blinded, Randomized, Parallel Group Superiority Trial
por: Samoud, Samar, et al.
Publicado: (2023)

CoronaVac efficacy data from Turkey
por: McMenamin, Martina E, et al.
Publicado: (2021)

Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers
por: Çulpan, Hazal Cansu, et al.
Publicado: (2023)

CoronaVac: more data for regulators and policy makers
por: Ramasamy, Maheshi N, et al.
Publicado: (2021)

Minimal change disease following vaccination with CoronaVac
por: Dirim, Ahmet Burak, et al.
Publicado: (2021)

Humoral Immune Response to CoronaVac in Turkish Adults
por: Cosgun, Yasemin, et al.
Publicado: (2023)

ANCA-associated vasculitis following the CoronaVac vaccination
por: Ma, Yaohui, et al.
Publicado: (2022)

Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial
por: Li, Jingxin, et al.
Publicado: (2022)

Placental Transfer Immunity to the Newborns in a Twin Pregnant Women Vaccinated with Heterologous CoronaVac-ChAdOx1
por: Pongsatha, Saipin, et al.
Publicado: (2023)

CoronaVac efficacy data from Turkey – Authors' reply
por: Tanriover, Mine Durusu, et al.
Publicado: (2021)

Leukocytoclastic vasculitis after the third dose of CoronaVac vaccination
por: Oskay, T., et al.
Publicado: (2021)

Antibody dynamics post-Comirnaty and CoronaVac vaccination in Malaysia
por: Tan, Cheng Siang, et al.
Publicado: (2022)

Cutaneous reactions after CoronaVac and BioNTech vaccines
por: Öner, Ümran, et al.
Publicado: (2022)

A Randomized Clinical Trial Using CoronaVac or BNT162b2 Vaccine as a Third Dose in Adults Vaccinated with Two Doses of CoronaVac
por: Mok, Chris Ka Pun, et al.
Publicado: (2022)

Heterologous prime-boost with the mRNA-1273 vaccine among CoronaVac-vaccinated healthcare workers in Indonesia
por: Santi, Theresia, et al.
Publicado: (2022)

IgA antibody dynamics in healthcare workers after CoronaVac® vaccination and heterologous Comirnaty® booster dose
por: Bochnia-Bueno, Lucas, et al.
Publicado: (2023)

Evaluation and follow-up of antibody formation after CoronaVac vaccine
por: Çalişir, Büşra, et al.
Publicado: (2022)

Phenotypic and functional changes of T cell subsets after CoronaVac vaccination
por: Phoksawat, Wisitsak, et al.
Publicado: (2022)

Waning effectiveness of CoronaVac in real life: A retrospective cohort study in health care workers
por: Can, Gunay, et al.
Publicado: (2022)

Comparative Safety and Effectiveness of Heterologous CoronaVac–ChAdOx1 versus Homologous CoronaVac Vaccination in a Real-World Setting: A Retrospective Cohort Study
por: Ruenkham, Ayakarn, et al.
Publicado: (2023)

BNT162b2 or CoronaVac as the Third Dose against Omicron: Neutralizing Antibody Responses among Transplant Recipients Who Had Received Two Doses of CoronaVac
por: Erol, Çiğdem, et al.
Publicado: (2023)

Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey
por: Riad, Abanoub, et al.
Publicado: (2021)

Reduced CoronaVac vaccine antibody response in patients with chronic kidney disease
por: Akpolat, Tekin
Publicado: (2021)

CoronaVac or BNT162b2 Vaccine as a Third Dose
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Neutralizing antibodies induced by homologous and heterologous boosters in CoronaVac vaccines in Chile
por: Acevedo, Johanna, et al.
Publicado: (2023)

Longitudinal evaluation of innate immune responses to three doses of CoronaVac vaccine
por: Cao, Cheng, et al.
Publicado: (2023)

Role of quantitative hepatitis B surface antigen in predicting inactive carriers and HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients
por: Ungtrakul, Teerapat, et al.
Publicado: (2017)

Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy
por: Karacin, Cengiz, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6oj1u0besf0to287sp48v7bcji